Sort
82,697 grants matching “vaccine development”
Administrative Core
$6,781,491Sumit K Chanda · Scripps Research Institute, The · U19 · FY2022 · AI
HIV/AIDS Vaccine Development
$6,779,015Gary J Nabel · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Novel Innate Immune Adjuvant for Avian Influenza and West Nile Virus Vaccines
$6,770,054Michael Gale · University Of Washington · N01 · FY2013 · AI
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
$6,753,999Robert A Wood · Johns Hopkins University · UM2 · FY2022 · AI
Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection
$6,749,208Chad Roy · Tulane University Of Louisiana · N01 · FY2020 · AI
Developing Broad-Spectrum Antivirals Targeting Coronavirus Replicase and Helicase
$6,734,714Timothy Patrick Sheahan · Univ Of North Carolina Chapel Hill · U19 · FY2022 · AI
SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD (SPIROMICS) III - TASK AREA A
$6,734,645Erica Anderson · · N01 · FY2024 · HL
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative Supplement
$6,714,942Eric Hunter · Emory University · UM1 · FY2021 · AI
Next Generation Development of Broadly Neutralizing HIV Antibodies for Prevention
$6,699,227John Mascola · Advanced Bioscience Laboratories, Inc. · N01 · FY2019 · AI
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
$6,692,860Avrum E Spira · Boston University Medical Campus · U2C · FY2018 · CA
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,665,131Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
HIV Vaccine Studies
$6,646,753Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Center for Research in Diagnostics and Discovery
$6,626,745W. Ian Lipkin · Columbia University Health Sciences · U19 · FY2017 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS
$6,620,891Richard Webby · St. Jude Children'S Research Hospital · N01 · FY2020 · AI
Antiviral Efficacy and Resistance Core
$6,599,276John Damon Chodera · Sloan-Kettering Inst Can Research · U19 · FY2022 · AI
Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune Profiling
$6,588,156Gregory A. Poland · Mayo Clinic Rochester · U01 · FY2013 · AI
Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV
$6,573,776Niranjan Sardesai · Viral Genomix, Inc. · N01 · FY2009 · AI
Consortium for AIDS Vaccine Research in Nonhuman Primates
$6,572,396Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2013 · AI
NHP MHC Gene Discovery and Typing Technology Development
$6,569,785David O'Connor · University Of Wisconsin-Madison · N01 · FY2011 · AI
Clinical Development of a Dengue Vaccine
$6,565,626Hawaii Biotech, Inc. · UC1 · FY2004 · AI
CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LAB
$6,554,653Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI
Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA
$6,535,818Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$6,531,361Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Core B - Facility Maintenance and Operation Core
$6,527,330Thomas Gary Ksiazek · University Of Texas Med Br Galveston · UC7 · FY2024 · AI
Core B - Facility Maintenance and Operation Core
$6,526,390Thomas Gary Ksiazek · University Of Texas Med Br Galveston · UC7 · FY2021 · AI